Clinical Trial Update: Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for TGR-1202 in patients with chronic lymphocytic leukemia intolerant to prior therapy; the study was terminated and results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• TGR-1202 (umbralisib)

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2024-07-03